Expedeon AG, formally SYGNIS AG, is a stock-listed company based in Heidelberg, Germany. Following strong support from investors, in July 2018, the company changed its company name from SYGNIS AG to Expedeon AG to pull its parent brand in-line with its customer offering.
2018: Following strong support from investors, SYGNIS AG formally changed its company name to Expedeon AG to pull its parent brand in-line with its customer offering.
2018: The company completed the aquisition of Australian research reagents company, TGR Biosciences, in May 2018. TGR and its highly complementary technologies and products along with its strong customer base significantly contribute to the overall performance of the Group.
2017: Acquisition of Innova Biosciences Ltd, a UK based immunoreagents company. This acquisition not only provided the group with complementary products and an innovative technology base but also enabled extensive cross selling opportunities through the company’s automated e-marketing platform. The integration of Innova Biosciences into the group was completed in March 2018.
2017: SYGNIS acquired C.B.S. Scientific, an acquisition that delivered scale in the US operations in addition to strengthening the electrophoresis product portfolio. C.B.S. Scientific was fully integrated by the end of the first quarter 2017.
2016: In 2016 SYGNIS acquired Expedeon. The acquisition enhanced the company’s product portfolio, and allowed for improved commercialisation of their products and technologies through an enhanced sales and marketing infrastructure.
2012: The company realigned its business, moving away from drug development activities, and merged with with X-Pol Biotech which transformed the Company to become a developer of molecular biology products for genomic and proteomic applications.
2006: The Company realigned in the field of drug development and was renamed as SYGNIS Pharma AG
2000: IPO at Frankfurt Stock Exchange
1997: The company was founded under the name LION Bioscience AG